A carregar...
Phase I/II Trial of Temsirolimus and Sorafenib in Treatment of Patients with Recurrent Glioblastoma: North Central Cancer Treatment Group Study/Alliance N0572
BACKGROUND: MAPK activation and mTOR-dependent signaling are hallmarks of glioblastoma. We conducted a phase I-II study of sorafenib (an inhibitor of Raf-kinase and VEGFR-2) and the mTOR inhibitor temsirolimus in recurrent glioblastoma. METHODS: Patients with recurrent glioblastoma progressing follo...
Na minha lista:
| Publicado no: | Cancer |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
2018
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5867230/ https://ncbi.nlm.nih.gov/pubmed/29313954 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.31219 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|